Targeted therapy for young patients

Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma

April 2024: The Food and Drug Administration (FDA) granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.). This approval is specifically for patients aged 6 months and ...
targeted-therapy-for-young-patients

Scan the code

Tag: Targeted therapy for young patients

Home / Targeted therapy for young patients

Categories

Tovorafenib has been granted accelerated approval by the FDA for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma

Information

Treatment

United States

Romania

India (Hyderabad)

Cambodia

China (Shanghai)

China (Beijing)

Hong Kong